LV305, a third-generation lentivirus-based vector, enhances expression of NY-ESO-1 in dendritic cells, and is tested in clinical trial against several tumour types such as sarcoma, ovarian, melanoma and lung cancers [106]. This evidence concerns the gene CTAG1B and lung cancer.